This activity was originally presented at the 2025 PTCE Cardiology Day of Education.
Program Description
Hyperlipidemia, characterized by high levels of low-density lipoprotein-cholesterol (LDL-C), is a public health issue and a leading cause of death globally. The first line of treatment for hyperlipidemia is statin therapy, but a significant number of patients face challenges in lowering their LDL-C levels to target levels. Several factors contribute to these challenges, including adherence, statin intolerance, and resistance. Over the past decade, several lipid-lowering therapies have emerged as alternatives or complementary therapies to address these challenges and improve outcomes for patients with hyperlipidemia. Pharmacists play a critical role in identifying patients who may not be adequately managed with their current therapeutic regimen or who would be considered candidates for non-statin LDL-C-lowering agents. This activity will explore the risk factors of atherosclerotic cardiovascular disease, hyperlipidemia management guidelines, and treatment options available. Faculty will include case-based discussion and review considerations for managing and monitoring patients with hyperlipidemia.
Target audience: Health System Pharmacists, Community Pharmacists, and Specialty Pharmacists
Type of activity: Application
Release date: June 13, 2025
Expiration date: June 13, 2026
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the impact of aggressive LDL-C reduction on cardiovascular outcomes in high-risk populations and how this informs treatment adjustments for complex cases
- Compare the efficacy, safety, and indications of nonstatin lipid-lowering therapies in achieving LDL-C targets in patients with hyperlipidemia who are at elevated atherosclerotic cardiovascular disease risk
- Develop patient education strategies that effectively communicate the importance of lipid-lowering therapies, focusing on adherence and long-term cardiovascular risk reduction
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here